Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

Abstract

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6). Results confirm intravenous peramivir's usefulness.

Keywords

• Aging
• Antiviral drugs
• Geriatrics
• Gerontology
• High-risk patient
• Neuraminidase inhibitor